Status:
COMPLETED
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
Lead Sponsor:
AstraZeneca
Conditions:
Colorectal Neoplasms
Melanoma
Eligibility:
All Genders
18-130 years
Phase:
PHASE2
Brief Summary
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
Eligibility Criteria
Inclusion
- The subject must have already received tremelimumab in another protocol
- Females of childbearing potential must agree to practice a form of effective contraception for 12 months following any dose of study drug. The definition of effective contraception will be based on the judgement of the investigator.
- Subject must be willing and able to provide written informed consent and to comply with scheduled visits and other trial procedures
Exclusion
- None
Key Trial Info
Start Date :
March 5 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 27 2023
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00378482
Start Date
March 5 2007
End Date
October 27 2023
Last Update
August 22 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Los Angeles, California, United States, 90024
2
Research Site
Tampa, Florida, United States, 33612
3
Research Site
Ann Arbor, Michigan, United States, 48109
4
Research Site
New York, New York, United States, 10016